DNA Methylation Clinical Trial
— GEMOfficial title:
DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise
Verified date | July 2023 |
Source | University of Colorado, Boulder |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Specific aim 1. Using a fully crossed 2 (intensity) X 2 (duration) design, the investigators will demonstrate a dose-response relationship between volume of aerobic exercise and changes in DNA methylation over four months among previously sedentary women. Specific aim 2. There are no published data on the extent to which positive effects of exercise on methylation might decay if exercise is not continued. The investigators will gather data on the natural history of methylation decay after training.
Status | Completed |
Enrollment | 276 |
Est. completion date | September 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 30 Years to 45 Years |
Eligibility | Inclusion Criteria: - Female - Age 30-45 - Sedentary (i.e., < 40 minutes per week of moderate physical activity in the past 6-months; this criterion will be relaxed to <60 minutes per week if it limits enrollment) - Menstruating regularly (not amenorrheic or dysmenorrheic) - Non-smokers - Willing to accept random assignment to condition - Willing to provide blood and saliva samples for epigenetic analysis - Willing to and physically capable of safely engaging in moderate exercise activity (i.e., no injuries, physical impairments, or pre-existing contraindications) as assessed by a study physician - Able to successfully complete a VO2max test without evidence of cardiac or other abnormalities - Planning to remain in the Denver metro area for the next 10 months Exclusion Criteria: - Have a BMI > 35kg/m2 - Are diabetic or on a restricted diet - Have uncontrolled hypertension defined as resting systolic BP >150 mmHg or diastolic BP>90 mmHg (to be assessed during physical exam, not on phone screen). (Participants who do not meet these criteria at first screening will be re-evaluated, including after follow-up evaluation by the primary care physician with initiation or adjustment of anti-hypertensive medications) - Have a cardiovascular or respiratory disease including subjective or objective indicators of ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the maximal exercise test (VO2max). (Participants who do not meet these criteria at first screening will be re-evaluated; follow-up evaluation must include diagnostic testing (e.g., thallium stress test) with interpretation by a cardiologist) - Have a history of breast neoplasia - Are currently receiving treatment for any type of cancer - Are on psychotropic medications - Are currently under treatment for any psychiatric disorder - Are currently under treatment for alcohol or drug abuse - Are currently pregnant or attempting to become pregnant in the next 6-months |
Country | Name | City | State |
---|---|---|---|
United States | Image Lab/ University of Colorado Denver | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Boulder | National Cancer Institute (NCI), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DNA METHYLATION | 4 months post-exercise initiation and 6 months after the end of the exercise intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03642574 -
Preimplantation DNA Methylation Test (PIMT) in ART
|
N/A | |
Completed |
NCT03787849 -
Epigenetics in PostOperative Pediatric Emergence Delirium
|
N/A | |
Recruiting |
NCT05442125 -
First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization
|
N/A | |
Recruiting |
NCT05624827 -
The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)
|
N/A | |
Completed |
NCT05085847 -
Effects of Mindfulness-based Intervention on Epigenetic Mechanisms, Cognition Function, Stress Response, and Well-being
|
N/A | |
Recruiting |
NCT04651946 -
Cell-free DNA Methylation for Epithelial Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT04646954 -
DNA Methylation Testing for the Screening of Uterine Cervical Lesion
|
Phase 3 | |
Recruiting |
NCT03961191 -
DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
|
||
Not yet recruiting |
NCT05779904 -
Methylation, mIcrobiome, NUtritional sTatus, and dEvelopment of Stunted Children
|
||
Recruiting |
NCT05791149 -
Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity
|
N/A | |
Recruiting |
NCT05801276 -
ctDNA Methylation for Detecting Ovarian Cancer
|
||
Recruiting |
NCT05801263 -
ctDNA Methylation for Epithelial Ovarian Cancer
|
||
Recruiting |
NCT05290415 -
Host DNA Methylation for Endometrial Cancer Screening
|
||
Recruiting |
NCT05290428 -
DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening
|
||
Recruiting |
NCT05290922 -
DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening
|
||
Recruiting |
NCT03960879 -
DNA Methylation for Screening Uterine Cervical Lesions
|
||
Recruiting |
NCT05737953 -
Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
|
||
Recruiting |
NCT06140992 -
PaCIFiC-CUP Classifies Cancer of Unknown Primary
|
||
Completed |
NCT04568512 -
DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture
|
N/A | |
Completed |
NCT03227003 -
DNA Methylation and 1-C Metabolism Nutrient Intake
|
N/A |